Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their ...